Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection
HLA · 2026
DOI: 10.1111/tan.71005 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2026. Verfasst von Aleksandra Gazikalovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Lung Transplantation, Graft Rejection. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
ddcfDNA emerged as a biomarker for post‐transplantation management strategies. Lung retransplant recipients represent a particularly vulnerable patient population with an increased risk of allograft injury. The demand for understanding if ddcfDNA levels differ between primary lung transplant recipients and lung retransplant recipients becomes obvious. Eight lung retransplant recipients and 50 primary lung transplant recipients with comparable HLA Class I and Class II mismatch scores were included in this retrospective study. During post‐transplant monitoring, ddcfDNA results were evaluated alongside data on patient humoral immune responses pre‐ and post‐transplantation. Antibody profiles of lung retransplant recipients did not differ significantly from those of their primary transplant comparisons. However, significantly higher ddcfDNA levels were observed in the retransplant cohort (median: 1.463%, IQR: 0.810–2.745) compared with primary transplant cohort (median: 0.550%, IQR: 0.338–0.935), U = 100.50, Z = −2.24, p = 0.012, r = 0.29. We identified that lung retransplant recipients exhibit increased allograft injury not solely attributable to humoral responses. Our study highlights that these patients face a higher immunological risk and supports the need for closer clinical follow‐up using a resilient biomarker such as ddcfDNA. Incorporating ddcfDNA as a surrogate marker into post‐transplant monitoring would provide early and unambiguous insights into allograft rejection, enabling prompt interventions to prevent unfavourable outcomes in this particularly fragile patient group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
- Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
ORCID-Profile: Aleksandra Gazikalovic, Murielle Verboom, Michael Hallensleben, Rainer Blasczyk, Jens Gottlieb, Funmilola Josephine Haukamp
Zitieren
APA
Gazikalovic, A., Bade-Döding, C., Verboom, M., Zirzow, S., Hallensleben, M., Blasczyk, R., Gottlieb, J., & Haukamp, F. J. (2026). Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection. HLA. https://doi.org/10.1111/tan.71005
Vancouver
Gazikalovic A, Bade-Döding C, Verboom M, Zirzow S, Hallensleben M, Blasczyk R, et al. Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection. HLA. 2026. doi:10.1111/tan.71005
BibTeX
@article{Gazikalovic2026,
author = {Gazikalovic, Aleksandra and Bade-Döding, Christina and Verboom, Murielle and Zirzow, Susann and Hallensleben, Michael and Blasczyk, Rainer and Gottlieb, Jens and Haukamp, Funmilola Josephine},
title = {Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection},
journal = {HLA},
year = {2026},
doi = {10.1111/tan.71005}
}
EUVIMED